PALO ALTO, Calif., Aug. 18, 2026 /PRNewswire/ -- Most companies now use AI. Very few operate as AI-native businesses. The gap between the two is where Converge AI is building.
Converge AI is bringing its specialized AI products together into a unified AI-native platform. With Converge Work now available at work.converge.ai, the platform's knowledge-work layer is live for business teams alongside Enter Pro, Framia Pro, and Combos Fun, with Concat Pro joining as integration continues. Across the suite, Converge AI's products operate on a shared context layer, allowing knowledge, work, and decisions created in one part of the business to carry forward into the next.
The first wave of business AI gave teams access to powerful models and point tools. Adoption, for most companies, has stayed fragmented. Teams run one tool for writing, another for design, another for code, another for analytics, and still struggle to connect that work across context, assets, and outcomes. The challenge in business AI is no longer access or awareness. It is operationalization: turning isolated AI outputs into repeatable workflows that carry across teams, systems, and business processes.
Converge AI is built around that problem. Rather than adding another standalone product to an already crowded stack, it brings specialized AI products into one environment where they share business context. Each product serves a distinct function:
Converge Work is the knowledge-work layer and default workspace of Converge AI. Powered by enterprise-grade User Context, it holds the knowledge, tools, and ongoing projects relevant to a team's work so that AI agents can act with continuity rather than start from scratch each time. Teams can build custom agents tailored to specific roles, turning institutional knowledge into reusable capability across research, documents, slides, and web deliverables.
Enter Pro is the builder layer. It lets teams turn an operational need into working web apps or a custom AI agent by describing what they want, with the full production stack behind it, from databases and authentication to hosting, payments, and analytics. Teams can build and ship software products, applications, portals, internal tools, and workflows without heavy engineering involvement.
Framia Pro is the creative layer. Through an agent-led workflow canvas, teams convert an idea into upload-ready video, design, and audio in minutes rather than days, directing genre-specific creative agents by natural conversation rather than crafted prompts. Acting as experienced creative directors, these agents manage end-to-end workflows spanning social-first UGC clips, music videos, enterprise brand kits, and professional film and TV productions.
Combos Fun is Converge AI's game and interactive content layer, powered by Boo, a personal AI game agent that turns prompts, sketches, or story ideas into playable games. Boo partners with creators to refine concepts, build game design documents, and deploy shareable builds. Within the Combos Fun community, every game is built to be discovered, played, remixed, and reimagined, turning individual ideas into shared collaborative worlds.
Concat Pro is the growth layer. Built as an AI-native growth OS powered by a self-learning AI CMO, it connects creator partnerships, SEO and GEO content, ads, websites, and publishing under a shared understanding of the brand, learning from performance data and improving with each campaign.
Because these products share context rather than sit side by side, a team can move from building a tool, to producing the creative around it, to launching and analyzing the result, without rebuilding context at each step. That coordination, rather than the number of tools, is what Converge AI is designed to deliver.
An AI-native business, in the way Converge AI sees the category, is not one that uses more AI tools. It is one that redesigns how work gets created, executed, distributed, and measured with AI embedded in the workflow, and with people and specialized agents working from the same context.
"The last few years showed every company what AI can do. The real question now is what a business looks like when AI is woven through everything it does, not bolted on at the edges," said Oliver Zhang, founder and CEO of Converge AI. "We are building Converge AI for that future: a unified environment where people across roles and specialized AI agents collaborate with shared context and purpose, carrying the knowledge of the business from one piece of work to the next. The most capable companies of the next decade will not be the ones with the most AI tools. They will be the ones that bring people and AI together, with human judgment setting the direction, human creativity opening new ground, and AI turning ambition into action."
Converge AI is rolling out to business teams across the United States through a staged release. To learn more, visit converge.ai.
About Converge AI
Converge AI is an all-in-one AI platform that helps businesses turn ideas into execution. Its specialized AI products share context across teams, automating workflows and delivering business results. The product suite includes Converge Work for context-aware AI workflows, Enter Pro for building and shipping tools and software with AI, Framia Pro for creative and campaign production, Concat Pro for growth intelligence, and Combos Fun for creating playable games and interactive experiences. Together they help teams and businesses of all sizes work faster and turn fragmented AI tasks into coordinated, repeatable workflows. Learn more at converge.ai.
Media contact:
Eric Zhang
ericz@converge.ai
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Converge AI Connects Its Specialized AI Products Into One Platform for Business Teams
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue
PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.
The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine.
GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability.
"Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery."
First-Half 2026 Highlights
GenScript Life Science Group
- Revenue of approximately US$319.0 million, up 28.8%
- Adjusted gross profit of approximately US$184.5 million, up 46.1%
- Adjusted operating profit of approximately US$94.0 million, up 102.8%
- Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine
AI-Enabled Drug Discovery
- AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period
- Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem
ProBio
- Revenue increased 34.2% on a comparable basis to approximately US$61.1 million
- New orders increased 54%
- Adjusted operating loss narrowed 22.5% to US$24.3 million
- Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027
Bestzyme
- Revenue of approximately US$30.4 million, up 7.4%
- Adjusted gross profit of approximately US$13.0 million, up 14.0%
Integrated Capabilities Support Growth Across the Portfolio
The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow.
GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers.
To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex.
Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development.
Outlook
GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses.
The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation.
Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website.
About GenScript Biotech Corporation
Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com.
Investor and Media Contacts
Investor Relations
Email: ir@genscript.com
Media Contact
Kate Grusich, Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
